COX2 inhibition reduces aortic valve calcification in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 938-947

  Wirrig, Elaine E ^a   Gomez, M Victoria ^a   Hinton, Robert B ^a   Yutzey, Katherine E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

aortic valve, calcification of; cyclooxygenase 2; heart valves

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; CELECOXIB; CYCLOOXYGENASE 2; OSTEOCALCIN; OSTEOPONTIN; TRANSCRIPTION FACTOR RUNX2; BETA GLUCURONIDASE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; KLOTHO PROTEIN; PTGS2 PROTEIN, HUMAN; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; AORTA VALVE DISEASE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CALCIFIC AORTIC VALVE DISEASE; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MARKER GENE; MOUSE; NONHUMAN; PORCINE AORTIC VALVULAR INTERSTITIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; 129 MOUSE; AGED; ANIMAL; C57BL MOUSE; CALCINOSIS; CASE CONTROL STUDY; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; HEART VALVE DISEASES; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; MUTANT MOUSE STRAIN; PATHOLOGY; PIG; POINT MUTATION; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; AORTIC VALVE; BIOMARKERS; CALCINOSIS; CASE-CONTROL STUDIES; CELECOXIB; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; GLUCURONIDASE; HEART VALVE DISEASES; HUMANS; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MIDDLE AGED; OSTEOGENESIS; POINT MUTATION; PYRAZOLES; SULFONAMIDES; SUS SCROFA; UP-REGULATION;

EID: 84933565032     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.305159     Document Type: Article

References (43)

1. Gohlke-Bärwolf C, Minners J, Jander N, Gerdts E, Wachtell K, Ray S, Pedersen TR. Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study. Curr Probl Cardiol. 2013;38:365-409. doi: 10.1016/j.cpcardiol.2013.06.003.
2. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011;8:162-172. doi: 10.1038/nrcardio.2010.202.
3. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124:1783-1791. doi: 10.1161/ CIRCULATIONAHA.110.006767.
4. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125:e2-e220. doi: 10.1161/ CIR.0b013e31823ac046.
5. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368:1005-1011. doi: 10.1016/S0140-6736(06)69208-8.
6. Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED; DEcIDE AVR (Developing Evidence to Inform Decisions about Effectiveness-Aortic Valve Replacement) Research Team. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. Circulation. 2013;127:1647-1655. doi: 10.1161/CIRCULATIONAHA.113.002003.
7. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009;119:1034-1048. doi: 10.1161/CIRCULATIONAHA.108.778886.
8. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184. doi: 10.1161/01. CIR.0000070591.21548.69.
9. Wirrig EE, Hinton RB, Yutzey KE. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol. 2011;50:561-569. doi: 10.1016/j.yjmcc.2010.12.005.
10. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-274. doi: 10.1038/nature03940.
11. Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/-/Lrp5-/-mice. J Cell Biochem. 2011;112:2987-2991. doi: 10.1002/jcb.23221.
12. Xu S, Gotlieb AI. Wnt3a/β-catenin increases proliferation in heart valve interstitial cells. Cardiovasc Pathol. 2013;22:156-166. doi: 10.1016/j. carpath.2012.06.008.
13. Yang X, Meng X, Su X, Mauchley DC, Ao L, Cleveland JC Jr, Fullerton DA. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2. J Thorac Cardiovasc Surg. 2009;138:1008-1015. doi: 10.1016/j.jtcvs.2009.06.024.
14. Cheek JD, Wirrig EE, Alfieri CM, James JF, Yutzey KE. Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol. 2012;52:689-700. doi: 10.1016/j.yjmcc.2011.12.013.
15. Thubrikar MJ, Aouad J, Nolan SP. Patterns of calcific deposits in operatively excised stenotic or purely regurgitant aortic valves and their relation to mechanical stress. Am J Cardiol. 1986;58:304-308.
16. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20:381-387. doi: 10.1681/ASN.2008040349.
17. Kuro-o M. A potential link between phosphate and aging-lessons from Klotho-deficient mice. Mech Ageing Dev. 2010;131:270-275.
18. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51. doi: 10.1038/36285.
19. Linefsky JP, O'Brien KD, Katz R, de Boer IH, Barasch E, Jenny NS, Siscovick DS, Kestenbaum B. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: The cardiovascular health study. J Am Coll Cardiol. 2011;58:291-297. doi: 10.1016/j. jacc.2010.11.073.
20. Chen Q, Rho JY, Fan Z, Laulederkind SJ, Raghow R. Congenital lack of COX-2 affects mechanical and geometric properties of bone in mice. Calcif Tissue Int. 2003;73:387-392. doi: 10.1007/s00223-002-0009-x.
21. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193-1226.
22. Robertson G, Xie C, Chen D, Awad H, Schwarz EM, O'Keefe RJ, Guldberg RE, Zhang X. Alteration of femoral bone morphology and density in COX-2-/-mice. Bone. 2006;39:767-772. doi: 10.1016/j. bone.2006.04.006.
23. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405-1415. doi: 10.1172/JCI15681.
24. Grosser T. Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. J Investig Med. 2009;57:709-716. doi: 10.231/JIM.0b013e3181b04d1f.
25. Narumiya S. Prostanoids and inflammation: A new concept arising from receptor knockout mice. J Mol Med (Berl). 2009;87:1015-1022. doi: 10.1007/s00109-009-0500-1.
26. Salvo F, Fourrier-Réglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A; Investigators of Safety of Non-Steroidal Anti-Inflammatory Drugs: SOS Project. Cardiovascular and gastrointestinal safety of NSAIDs: A systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89:855-866. doi: 10.1038/clpt.2011.45.
27. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080. doi: 10.1056/NEJMoa050405.
28. Hajdu Z, Romeo SJ, Fleming PA, Markwald RR, Visconti RP, Drake CJ. Recruitment of bone marrow-derived valve interstitial cells is a normal homeostatic process. J Mol Cell Cardiol. 2011;51:955-965. doi: 10.1016/j.yjmcc.2011.08.006.
29. Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporallycontrolled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis. 2009;47:14-18. doi: 10.1002/dvg.20448.
30. Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol. 2003;63:870-877.
31. Yu Y, Fan J, Chen XS, Wang D, Klein-Szanto AJ, Campbell RL, FitzGerald GA, Funk CD. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat Med. 2006;12:699-704. doi: 10.1038/nm1412.
32. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br. 2003;85:700-705.
33. Lau KH, Kothari V, Das A, Zhang XB, Baylink DJ. Cellular and molecular mechanisms of accelerated fracture healing by COX2 gene therapy: studies in a mouse model of multiple fractures. Bone. 2013;53:369-381. doi: 10.1016/j.bone.2013.01.003.
34. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol. 2004;200:400-406. doi: 10.1002/jcp.20031.
35. Choudhary S, Alander C, Zhan P, Gao Q, Pilbeam C, Raisz L. Effect of deletion of the prostaglandin EP2 receptor on the anabolic response to prostaglandin E2 and a selective EP2 receptor agonist. Prostaglandins Other Lipid Mediat. 2008;86:35-40. doi: 10.1016/j. prostaglandins.2008.02.001.
36. Gao Q, Xu M, Alander CB, Choudhary S, Pilbeam CC, Raisz LG. Effects of prostaglandin E2 on bone in mice in vivo. Prostaglandins Other Lipid Mediat. 2009;89:20-25. doi: 10.1016/j. prostaglandins.2009.03.003.
37. Jee WS, Ueno K, Kimmel DB, Woodbury DM, Price P, Woodbury LA. The role of bone cells in increasing metaphyseal hard tissue in rapidly growing rats treated with prostaglandin E2. Bone. 1987;8:171-178.
38. Minamizaki T, Yoshiko Y, Kozai K, Aubin JE, Maeda N. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone. 2009;44:1177-1185. doi: 10.1016/j.bone.2009.02.010.
39. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844-853.
40. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol. 1970;26:72-83.
41. Monzack EL, Masters KS. Can valvular interstitial cells become true osteoblasts? A side-by-side comparison. J Heart Valve Dis. 2011;20:449-463.
42. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255-266. doi: 10.1016/j.amjmed.2005.09.054.
43. Delaney JA, Lehmann N, Jöckel KH, et al. Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis. 2013;229:310-316. doi: 10.1016/j.atherosclerosis.2013.05.002.